| Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data P Bozzatello, E Brignolo, E De Grandi, S Bellino Journal of clinical medicine 5 (8), 67, 2016 | 221 | 2016 |
| The interplay among psychopathology, personal resources, context‐related factors and real‐life functioning in schizophrenia: stability in relationships after 4 years and … S Galderisi, P Rucci, A Mucci, A Rossi, P Rocca, A Bertolino, E Aguglia, ... World psychiatry 19 (1), 81-91, 2020 | 108 | 2020 |
| Early detection and outcome in borderline personality disorder P Bozzatello, S Bellino, M Bosia, P Rocca Frontiers in psychiatry 10, 446813, 2019 | 98 | 2019 |
| Predictive factors of treatment resistance in first episode of psychosis: a systematic review P Bozzatello, S Bellino, P Rocca Frontiers in psychiatry 10, 398503, 2019 | 83 | 2019 |
| The role of trauma in early onset borderline personality disorder: a biopsychosocial perspective P Bozzatello, P Rocca, L Baldassarri, M Bosia, S Bellino Frontiers in psychiatry 12, 721361, 2021 | 58 | 2021 |
| Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid S Bellino, P Bozzatello, G Rocca, F Bogetto Journal of Psychopharmacology 28 (2), 125-132, 2014 | 55 | 2014 |
| Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? P Bozzatello, P Rocca, ML De Rosa, S Bellino Expert Opinion on Pharmacotherapy 21 (1), 47-61, 2020 | 53 | 2020 |
| Borderline personality disorder: Risk factors and early detection P Bozzatello, C Garbarini, P Rocca, S Bellino Diagnostics 11 (11), 2142, 2021 | 51 | 2021 |
| Polyunsaturated fatty acids: what is their role in treatment of psychiatric disorders? P Bozzatello, P Rocca, E Mantelli, S Bellino International Journal of Molecular Sciences 20 (21), 5257, 2019 | 51 | 2019 |
| Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study S Bellino, E Paradiso, P Bozzatello, F Bogetto Journal of psychopharmacology 24 (3), 333-339, 2010 | 50 | 2010 |
| Pharmacotherapy of borderline personality disorder: A systematic review S Bellino, C Rinaldi, P Bozzatello, F Bogetto Current medicinal chemistry 18 (22), 3322-3329, 2011 | 45 | 2011 |
| Italian Network for Research on Psychoses. The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia … S Galderisi, P Rucci, A Mucci, A Rossi, P Rocca, A Bertolino, E Aguglia, ... World Psychiatry 19 (1), 81-91, 2020 | 38 | 2020 |
| Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial P Bozzatello, P Rocca, M Uscinska, S Bellino CNS drugs 31, 809-819, 2017 | 36 | 2017 |
| Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: A two-years follow-up P Bozzatello, S Bellino Psychiatry Research 240, 151-156, 2016 | 32 | 2016 |
| Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability S Bellino, P Bozzatello, C Rinaldi, F Bogetto Depression research and treatment 2011 (1), 680194, 2011 | 30 | 2011 |
| Unblending borderline personality and bipolar disorders E Di Giacomo, F Aspesi, M Fotiadou, A Arntz, E Aguglia, L Barone, ... Journal of Psychiatric Research 91, 90-97, 2017 | 29 | 2017 |
| Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: A follow-up study P Bozzatello, P Rocca, S Bellino Clinical drug investigation 38, 367-372, 2018 | 28 | 2018 |
| The impact of SARS-CoV-2 infection on youth mental health: a narrative review C Brasso, S Bellino, C Blua, P Bozzatello, P Rocca Biomedicines 10 (4), 772, 2022 | 27 | 2022 |
| Autobiographical memories, identity disturbance and brain functioning in patients with borderline personality disorder: An fMRI study P Bozzatello, R Morese, MC Valentini, P Rocca, F Bosco, S Bellino Heliyon 5 (3), 2019 | 26 | 2019 |
| Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia C Brasso, S Bellino, P Bozzatello, C Montemagni, P Rocca Neuropsychiatric disease and treatment, 2767-2779, 2017 | 26 | 2017 |
